Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Long-term Debt?

  Amgen Inc ( AMGN ) |
1986 - 2021 (36 years)

Long-term Debt is 
$133.0B (1Y +9.14% )

AMGN Stock Price & Long-term Debt

Long-term Debt for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Long-term Debt

chevron_right 2021 $32.9B +3915x
( +25.8% / year avg)
chevron_left 1986 $8.4M
vertical_align_top Peak $127.9B +18008x
vertical_align_bottom Bottom $7.1M
arrow_drop_up # Up Years 23 23 of 36
years up.
arrow_drop_down # Down Years 13
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1986 , or +0.29x the rate relative to it's long-term debt over the same period.
  • If AMGN grows it's stock at the same rate as it's long-term debt (+25.8%/year) , it's stock price will grow +992% and hit $2449.42 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 23 years (0%) it's long-term debt were also up.
  • AMGN Historical Long-term Debt Table
    in $ million
    Year Long-term Debt YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $32,895 -73.7% - -
    4/1/2020 $125,287 9.5% - -
    4/1/2019 $114,369 -10.0% - -
    4/1/2018 $127,107 -0.6% - -
    4/1/2017 $127,866 6.7% - -
    4/1/2016 $119,820 -1.2% - -
    4/1/2015 $121,269 0.7% - -
    4/1/2014 $120,450 21.7% - -
    4/1/2013 $99,005 14.7% - -
    4/1/2012 $86,354 74.7% - -
    4/1/2011 $49,426 23.4% - -
    4/1/2010 $40,046 -1.3% - -
    4/1/2009 $40,591 4.9% - -
    4/1/2008 $38,705 5.4% - -
    4/1/2007 $36,737 43.4% - -
    4/1/2006 $25,620 143.3% - -
    4/1/2005 $10,531 -22.6% - -
    4/1/2004 $13,604 11.2% - -
    4/1/2003 $12,238 30.7% - -
    4/1/2002 $9,364 949.8% - -
    4/1/2001 $892 33.3% - -
    4/1/2000 $669 -40.0% - -
    4/1/1999 $1,115 24.2% - -
    4/1/1998 $898 135.7% - -
    4/1/1997 $381 -12.3% - -
    4/1/1996 $434 -39.9% - -
    4/1/1995 $723 30.2% - -
    4/1/1994 $555 -14.0% - -
    4/1/1993 $645 42.5% - -
    4/1/1992 $453 490.4% - -
    4/1/1991 $76 -62.7% - -
    4/1/1990 $205 -13.6% - -
    4/1/1989 $238 1343.6% - -
    4/1/1988 $16 132.4% - -
    4/1/1987 $7 -15.5% - -
    4/1/1986 $8 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

  • Long Term Debt (LTD) is any amount of outstanding debt a company holds that has a maturity of 12 months or longer. It is classified as a non-current liability on the company's balance sheet. These statements are key to both financial modeling and accounting.

    For more detailed definitions, please see Investopedia.